30181529|t|Modulation of P2X Purinoceptor 3 (P2X3) in Pentylenetetrazole-Induced Kindling Epilepsy in Rats.
30181529|a|BACKGROUND Epilepsy is a complex neurologic disorder with abnormal electrical impulses in the brain. A crucial role of purinergic signalling in the proper working of the nervous system has been reported but much less is known about the modulation of P2X3 purinergic receptors in epilepsy. This study investigated the effect of NF110, a potent P2X3 receptor antagonist, in the rat epilepsy model of pentylenetetrazole (PTZ)-induced kindling. MATERIAL AND METHODS The mean kindling score, motor activity, locomotion, emotional tension, anxiety, discrimination ability, learning, memory, serum neuron-specific enolase (sNSE), hippocampal IL-1beta and TNF-alpha, thiobarbituric acid-reactive substance (TBARS), catalase (CAT) and reduced glutathione (GSH), and mitochondrial complex I, II, and IV levels of PTZ-kindling animals were assessed. RESULTS The PTZ-kindling animals have shown impaired motor activity, locomotion, discrimination ability, learning, and memory, along with increased emotional tension, anxiety, neuronal damage (increased sNSE), hippocampal pro-inflammatory mediators (increased IL-1beta and TNF-alpha), oxidative stress (increased TBARS, decreased GSH and CAT), and mitochondrial dysfunction. The administration of NF110 in 3 different doses has significantly and dose-dependently corrected PTZ-kindling-induced impaired behavior, learning, memory, locomotion, motor activity, discrimination ability, neuronal damage, hippocampal inflammation, oxidative stress, and mitochondrial dysfunction. These beneficial effects of NF110 in PTZ-kindling animals were significantly abolished by the administration of the P2X agonist alpha, beta methylene-ATP. CONCLUSIONS P2X3 receptors play a very important role in kindling epilepsy and further research should be done to design P2X3 modulators for their possible therapeutic benefits in epileptic disorders.
30181529	14	32	P2X Purinoceptor 3	Gene	81739
30181529	43	61	Pentylenetetrazole	Chemical	MESH:D010433
30181529	79	87	Epilepsy	Disease	MESH:D004827
30181529	91	95	Rats	Species	10116
30181529	108	116	Epilepsy	Disease	MESH:D004827
30181529	130	149	neurologic disorder	Disease	MESH:D009461
30181529	376	384	epilepsy	Disease	MESH:D004827
30181529	424	429	NF110	Chemical	MESH:C511626
30181529	473	476	rat	Species	10116
30181529	477	485	epilepsy	Disease	MESH:D004827
30181529	495	513	pentylenetetrazole	Chemical	MESH:D010433
30181529	515	518	PTZ	Chemical	MESH:D010433
30181529	600	610	locomotion	Disease	MESH:D020233
30181529	612	629	emotional tension	Disease	MESH:D018781
30181529	631	638	anxiety	Disease	MESH:D001007
30181529	688	711	neuron-specific enolase	Gene	24334
30181529	732	740	IL-1beta	Gene	24494
30181529	745	754	TNF-alpha	Gene	24835
30181529	756	794	thiobarbituric acid-reactive substance	Chemical	MESH:D017392
30181529	796	801	TBARS	Chemical	MESH:D017392
30181529	804	812	catalase	Gene	24248
30181529	814	817	CAT	Gene	24248
30181529	831	842	glutathione	Chemical	MESH:D005978
30181529	844	847	GSH	Chemical	MESH:D005978
30181529	868	889	complex I, II, and IV	Chemical	-
30181529	900	903	PTZ	Chemical	MESH:D010433
30181529	948	951	PTZ	Chemical	MESH:D010433
30181529	980	1003	impaired motor activity	Disease	MESH:D000068079
30181529	1005	1015	locomotion	Disease	MESH:D020233
30181529	1084	1101	emotional tension	Disease	MESH:D018781
30181529	1103	1110	anxiety	Disease	MESH:D001007
30181529	1112	1127	neuronal damage	Disease	MESH:D009410
30181529	1162	1174	inflammatory	Disease	MESH:D007249
30181529	1196	1204	IL-1beta	Gene	24494
30181529	1209	1218	TNF-alpha	Gene	24835
30181529	1249	1254	TBARS	Chemical	MESH:D017392
30181529	1266	1269	GSH	Chemical	MESH:D005978
30181529	1274	1277	CAT	Gene	24248
30181529	1284	1309	mitochondrial dysfunction	Disease	MESH:D028361
30181529	1333	1338	NF110	Chemical	MESH:C511626
30181529	1409	1412	PTZ	Chemical	MESH:D010433
30181529	1430	1447	impaired behavior	Disease	MESH:D001523
30181529	1467	1477	locomotion	Disease	MESH:D020233
30181529	1519	1534	neuronal damage	Disease	MESH:D009410
30181529	1536	1560	hippocampal inflammation	Disease	MESH:D007249
30181529	1584	1609	mitochondrial dysfunction	Disease	MESH:D028361
30181529	1639	1644	NF110	Chemical	MESH:C511626
30181529	1648	1651	PTZ	Chemical	MESH:D010433
30181529	1739	1764	alpha, beta methylene-ATP	Chemical	MESH:C002630
30181529	1832	1840	epilepsy	Disease	MESH:D004827
30181529	1946	1965	epileptic disorders	Disease	MESH:D009358
30181529	Positive_Correlation	MESH:D010433	MESH:D009410
30181529	Association	MESH:D010433	24248
30181529	Positive_Correlation	MESH:D007249	24494
30181529	Negative_Correlation	MESH:C511626	MESH:D001523
30181529	Positive_Correlation	MESH:D010433	MESH:D018781
30181529	Positive_Correlation	MESH:D010433	MESH:D017392
30181529	Negative_Correlation	MESH:C511626	MESH:D010433
30181529	Positive_Correlation	MESH:D010433	MESH:D001007
30181529	Positive_Correlation	MESH:D010433	MESH:D028361
30181529	Negative_Correlation	MESH:C511626	MESH:D009410
30181529	Positive_Correlation	MESH:D010433	MESH:D001523
30181529	Negative_Correlation	MESH:C511626	MESH:D028361
30181529	Association	MESH:D004827	81739
30181529	Positive_Correlation	MESH:D010433	MESH:D000068079
30181529	Negative_Correlation	MESH:D005978	24248
30181529	Negative_Correlation	MESH:D005978	MESH:D010433
30181529	Positive_Correlation	MESH:D010433	24835
30181529	Positive_Correlation	MESH:D010433	MESH:D004827
30181529	Negative_Correlation	MESH:C511626	MESH:D020233
30181529	Positive_Correlation	MESH:D010433	MESH:D020233
30181529	Positive_Correlation	MESH:D010433	24494
30181529	Negative_Correlation	MESH:C511626	MESH:D007249
30181529	Positive_Correlation	MESH:D010433	MESH:D007249

